• Kátia Sheylla Malta Purim, Murilo Calvo Peretti, José Fillus, and Marcia Olandoski.
• Discipline of Dermatology of the Medical School - Universidade Positivo (UP) - Curitiba (PR), Brazil.
• An Bras Dermatol. 2017 Jul 1; 92 (4): 478-483.

Background:Histological and mycological changes during itraconazole use have not been totally established in chromoblastomycosis.Objectives:To evaluate tissue modifications in chromoblastomycosis carriers under itraconazole treatment.Methods:A histological retrospective study of 20 cases of chromoblastomycosis seen at the university hospital at the south of Brazil, during itraconazole 400 mg daily treatment. Patients were classified into two groups: plaque or tumor lesions, and underwent periodic evaluations every four months during three years. Hematoxylin-eosin stain was used to analyze epidermal modifications, inflammatory infiltrate and fibrosis, and Fontana-Masson stain for parasite evaluation.Results:Fontana-Masson stain was superior to hematoxylin-eosin stain in fungal count in the epidermis (mean difference=0.14; p<0.05). The most distinct mycosis tissue responses were registered in the dermis. Epidermal thinning, granulomatous infiltrate decrease or disappearance, fibrosis increase and quantitative/morphological changes occurred during treatment.Study Limitations:Patients could not be located to have their current skin condition examined.Conclusion:Parasitic and tissue changes verified in this study can reflect the parasite-host dynamics under itraconazole action.

30 keywords...

hide…